Introduction: Nitrosamine risk assessment and Nitrosamine Testing in ANDA Submissions refer to the regulatory process used to identify, measure, and […]
Nitrosamine Risk Assessment and Testing in ANDA Submissions: Regulatory Expectations Read More »
Introduction Pharmaceutical companies often receive regulatory questions about nitrosamine impurities during submissions, variations, or post-approval reviews. When this happens, organizations
How to Respond to a Regulatory Query on Nitrosamine Risk Assessment Read More »
Introduction Nitrosamine Reference Standard Qualification is an essential part of analytical testing used to detect and measure trace nitrosamine impurities
Qualification of Reference Standards for Nitrosamine Analytical Testing Read More »
Introduction to Nitrosamine Lifecycle Management Nitrosamine Lifecycle Management is essential for maintaining effective control of nitrosamine impurities after pharmaceutical products
Lifecycle Management of Nitrosamine Control Strategies Post-Approval Read More »
Introduction The Nitrosamine Risk in Solid vs Liquid Dosage forms has become a critical topic in pharmaceutical quality and regulatory
Nitrosamine Risk in Solid Oral Dosage vs Liquid Formulations: Comparative Analysis Read More »
Introduction: In recent years, the pharmaceutical industry has faced several major product recalls linked to nitrosamine contamination. A detailed Nitrosamine
Trending Nitrosamine Recalls: Lessons Learned from Global Regulatory Actions Read More »
Introduction Nitrosamine Testing for OTC Products demands a risk-based and stability-focused approach that goes beyond traditional impurity testing. Over-the-counter medicines
Nitrosamine Testing for Over-the-Counter (OTC) Products: Special Considerations Read More »
Introduction Nitrosamine Testing in Combination Products presents greater scientific and regulatory challenges than testing single-API drug products. When multiple APIs
Nitrosamine Testing in Combination Drug Products: Managing Multiple APIs Read More »
Introduction In pharmaceutical manufacturing, understanding Nitrosamine Alert Limit vs Action Limit is critical for compliance and patient safety. The distinction
Setting Alert Limits vs Action Limits for Nitrosamines: Practical Implementation Guide Read More »
Introduction: The Nitrosamine Batch Release Testing Requirement becomes mandatory when confirmatory testing shows nitrosamine impurity levels above 10% of the
Nitrosamine Batch Release Testing: When Is Routine Testing Required? Read More »
